A unique resource for well-annotated cancer clinical trial biospecimens to enable biomarker discovery and improve cancer treatment.
Who We Are
The National Clinical Trials Network (NCTN) Biospecimen Banks (NCTN Biobanks) receive, store, and distribute human biospecimens collected on NCTN clinical trials. NCTN Biobanks provide cancer researchers with quality, well-annotated biospecimens with associated clinical information. Requests for NCTN Biospecimens from completed NCTN clinical trials may be submitted by investigators in the research community, not only members of the NCTN Groups.
About the NCTN Biobanks
THE NCTN Biobanks receive, store, and distribute biospecimens for the five NCTN Groups as well as the Canadian Cancer Trials Group (CCTG):
Collectively, the NCTN Biobanks house solid tumor biospecimens from all organ types, as well as hematological malignancies.
Biospecimen types available include, but are not limited to:
- Formalin-fixed, paraffin-embedded (FFPE) tissue
- Fresh frozen tissue
- Whole blood, serum, plasma, white blood cells, bone marrow and cells
- Nucleic acids
- Urine, stool
Notable publications illustrating the important scientific contributions resulting from the use of NCTN Biobank resources.
Publication from NRG Oncology
This study resulted in a paradigm shift in the clinical management of colorectal cancer by showing the important role for CDX2 testing of patients with stage II cancer who may benefit from adjuvant therapy if their tumor is CDX2 negative.
Publication from Children's Oncology Group
This study identified 106 putative driver genes, half of which had not previously been described in childhood T-ALL (for example, CCND3, CTCF, MYB, SMARCA4, ZFP36L2 and MYCN). They described new mechanisms of coding and noncoding alteration and identified ten recurrently altered pathways with associations between mutated genes and pathways, and stage or subtype of T-ALL.
Publication from ECOG-ACRIN
This analysis provided proof of concept and laid the foundation for designing additional clinical trials that would obtain more information on the clinical usefulness of the 21-gene assay in women with hormone-receptor–positive breast cancer and positive axillary nodes and evaluating the clinical usefulness of a more extended 50-gene assay in this context.
Publication from Alliance
This study highlighted the complexity of predicting response in HER2-positive breast cancer and established the groundwork for applying a precision medicine approach to the treatment of patients with Her2-positive breast cancer.
Publication from SWOG
This research showed that follicular lymphoma patients who were vitamin D deficient had worse progression-free and overall survival rates.
Publication from Canadian Cancer Trials Group
This publication is one of many that has resulted from a unique collaboration of international groups who led 4 adjuvant trials in early stage lung cancer. This study explored the underlying biology of early stage NSCLC, and its response to current treatment using both conventional histology/immunohistochemistry, as well as genomic approaches.
Biospecimens from completed NCTN clinical trials can be requested either via NCTN Navigator or the NCTN Group’s Biospecimen Access process. In both instances, investigators will be provided with a feasibility assessment and cost estimate upon review of the request.
NCTN biospecimens are available to investigators from the cancer research community based on a review and approval by the NCTN Core Correlative Sciences Committee (NCTN-CCSC).
2 Ways to Request Biospecimens
NCTN Navigator is limited to biospecimens collected from NCTN trials that were:
- phase 2/3, phase 3, or large biospecimen collection protocols with clinical data;
- activated 1995 or later (with some exceptions); and
- completed with the primary outcome reported.
Information about the NCTN Navigator process is available on the NCTN Navigator website. Detailed instructions and important information about the request process are provided in the NCTN Navigator FAQs.
Information about the scientific review process for proposals submitted through NCTN Navigator is available on the NCTN Core Correlative Sciences Committee (NCTN-CCSC) website.
Biospecimens not available via NCTN Navigator may be requested through the NCTN Group. Please refer to the appropriate NCTN Group for additional information.
In general, the NCTN Group process mirrors that of NCTN Navigator. Briefly, investigators are required to submit a letter of intent (LOI) for Group feasibility assessment. If the LOI is feasible, investigators will be required to complete a proposal packet for scientific review by the NCI.
Note: If requesting biospecimens from more than one trial and at least one trial is in NCTN Navigator, then the entire request must be submitted through NCTN Navigator.
NCI Specimen Resource Locator
This is a database to help researchers locate human specimens (e.g., tissue, serum, DNA/RNA, other specimens) for cancer research.
This is a database of privately and publicly funded clinical studies conducted around the world.
The CHTN is a unique NCI supported resource that provides human tissues and fluids from routine procedures to investigators who utilize human biospecimens in their research. Unlike tissue banks, the CHTN works prospectively with each investigator to tailor specimen acquisition and processing to meet their specific project requirements.
National Disease Research Interchange
NDRI distributes biospecimens to hundreds of investigators around the world who are working to advance many areas of science and healthcare. NDRI makes it easy for approved investigators to get much-needed biospecimens prepared, preserved and shipped precisely according the specific needs of the research protocol.
NCI Biospecimen Research Database
The Biospecimen Research Database is a free and publicly accessible database that contains peer-reviewed primary and review articles as well as standard operating procedures (SOPs) in the field of human biospecimen science.
NHLBI BioLINCC Biospecimen and Data Repository
The mission of BioLINCC is to facilitate access to, and maximize the scientific value of, the Biorepository and Data Repository and promote the availability and use of other NHLBI funded population-based biospecimen and data resources.
NIDDK Central Repository
The NIDDK has established data, biospecimens, and genetic repositories to increase the impact of current and previously funded NIDDK studies by making their data and biospecimens available to the broader scientific community.